The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

Trends in Pharmacological Sciences

Volumn 39, Issue 7, 2018, Pages 635-647

  Ju, Lin Cheng ^a,b   Cheng, Zishuo ^b   Fast, Walter ^c   Bonomo, Robert A ^d,e   Crowder, Michael W ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b MIAMI UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

inhibitor; mechanism; metallo lactamase; spectroscopy

Indexed keywords

ENZYME INHIBITOR; METAL ION; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE INHIBITOR; UNCLASSIFIED DRUG; ZINC ION; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

COMPLEX FORMATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; IC50; METAL BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR MODEL;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CATALYTIC DOMAIN; DRUG RESISTANCE, MICROBIAL; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85045904792     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2018.03.007     Document Type: Review

References (72)

1. Rojas, L.J., et al. NDM-5 and OXA-181 β-lactamases, a significant threat continues to spread in the Americas. Antimicrob. Agents Chemother., 61, 2017 e00454-17.
2. Chen, L., et al. Notes from the field: pan-resistant New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae – Washoe County, Nevada, 2016. MMWR Morb. Mortal. Wkly. Rep., 66, 2017, 33.
3. Fisher, J.F., et al. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105 (2005), 395–424.
4. Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors in the clinic. Infect. Dis. Clin. North Am. 30 (2016), 441–464.
5. Makena, A., et al. Biochemical characterization of New Delhi metallo-β-lactamase variants reveals differences in protein stability. J. Antimicrob. Chemother. 70 (2015), 463–469.
6. Makena, A., et al. Comparison of Verona integron-borne metallo-β-lactamase (VIM) variants reveals differences in stability and inhibition profiles. Antimicrob. Agents Chemother. 60 (2015), 1377–1384.
7. Stewart, A.C., et al. Clinical variants of New Delhi metallo-β-lactamase are evolving to overcome zinc scarcity. ACS Infect. Dis. 3 (2017), 927–940.
8. Bahr, G., et al. Clinical evolution of New Delhi metallo-β-lactamase (NDM) optimizes resistance under Zn(II) deprivation. Antimicrob. Agents Chemother., 62, 2018 e01849-17.
9. Meini, M.R., et al. Overcoming differences: the catalytic mechanism of metallo-β-lactamases. FEBS Lett. 589 (2015), 3419–3432.
10. Potter, R.F., et al. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist. Updat. 29 (2016), 30–46.
11. Fast, W., Sutton, L.D., Metallo-β-lactamase: inhibitors and reporter substrates. Biochim. Biophys. Acta 1834 (2013), 1648–1659.
12. González, M.M., Vila, A.J., An elusive task: a clinically useful inhibitor of metallo-β-lactamases. Supuran, C.T., Capasso, C., (eds.) Zinc Enzyme Inhibitors: Enzymes from Microorganisms, 2017, Springer, 1–34.
13. McGeary, R.P., et al. Progress toward inhibitors of metallo-β-lactamases. Future Med. Chem. 9 (2017), 673–691.
14. Rotondo, C.M., Wright, G.D., Inhibitors of metallo-β-lactamases. Curr. Opin. Microbiol. 39 (2017), 96–105.
15. Drawz, S.M., Bonomo, R.A., Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23 (2010), 160–201.
16. Klingler, F.M., et al. Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria. J. Med. Chem. 58 (2015), 3626–3630.
17. Buttner, D., et al. Challenges in the development of a thiol-based broad-spectrum inhibitor for metallo-β-lactamases. ACS Infect. Dis. 4 (2018), 360–372.
18. Park, B.K., et al. Metabolic activation in drug allergies. Toxicology 158 (2001), 11–23.
19. Leigh, R., Eva, F., An introduction to biologics and biosimilars. Part II: subsequent entry biologics: biosame or biodifferent?. Can. Pharmacists J. 143 (2010), 184–191.
20. Xiang, Y., et al. Azolylthioacetamides as a potent scaffold for the development of metallo-β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 27 (2017), 5225–5229.
21. Holdgate, G.A., et al. Mechanistic enzymology in drug discovery: a fresh perspective. Nat. Rev. Drug Discov. 17 (2018), 115–132.
22. Sabath, L.D., Abraham, E.P., Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem. J. 98 (1966), 11c–13c.
23. Pitout, J.D., et al. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob. Agents Chemother. 59 (2015), 5873–5884.
24. King, A.M., et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510 (2014), 503–506.
25. Albu, S.A., et al. Total synthesis of aspergillomarasmine A and related compounds: a sulfamidate approach enables exploration of structure–activity relationships. Angew. Chem. Int. Ed. Engl. 55 (2016), 13259–13262.
26. Koteva, K., et al. Total synthesis and activity of the metallo-β-lactamase inhibitor aspergillomarasmine A. Angew. Chem. Int. Ed. Engl. 128 (2016), 2250–2252.
27. Bergstrom, A., et al. Probing the interaction of aspergillomarasmine A with metallo-β-lactamases NDM-1, VIM-2, and IMP-7. ACS Infect. Dis. 4 (2017), 135–145.
28. Brem, J., et al. Structural basis of metallo-β-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother. 60 (2015), 142–150.
29. Chen, A.Y., et al. Dipicolinic acid derivatives as inhibitors of New Delhi metallo-β-lactamase-1. J. Med. Chem. 60 (2017), 7267–7283.
30. Lienard, B.M., et al. Dynamic combinatorial mass spectrometry leads to metallo-β-lactamase inhibitors. J. Med. Chem. 51 (2008), 684–688.
31. De Vriendt, K., et al. Monitoring the zinc affinity of the metallo-β-lactamase CphA by automated nanoESI-MS. J. Am. Soc. Mass Spectrom. 17 (2006), 180–188.
32. Selevsek, N., et al. Studies on ternary metallo-beta lactamase–inhibitor complexes using electrospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 17 (2006), 1000–1004.
33. Lienard, B.M., et al. Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols. Org. Biomol. Chem. 6 (2008), 2282–2294.
34. Cuniasse, P., et al. Structures of biomolecular complexes by combination of NMR and cryoEM methods. Curr. Opin. Struct. Biol. 43 (2017), 104–113.
35. 67ZnNMR, a tool for coordination chemistry problems. Marek, I., Rappoport, Z., (eds.) Patai's Chemistry of Functional Groups, 2009, John Wiley & Sons, 147–161.
36. Tierney, D.L., Schenk, G., X-ray absorption spectroscopy of dinuclear metallohydrolases. Biophys. J. 107 (2014), 1263–1272.
37. Pievo, R., et al. A rapid freeze–quench setup for multi-frequency EPR spectroscopy of enzymatic reactions. Chemphyschem 14 (2013), 4094–4101.
38. Bennett, B., EPR of cobalt-substituted zinc enzymes. Hanson, G., Berliner, L., (eds.) Metals in Biology: Applications of High-Resolution EPR to Metalloenzymes, 2010, Springer, 345–370.
39. Yang, H., et al. Spectroscopic and mechanistic studies of heterodimetallic forms of metallo-β-lactamase NDM-1. J. Am. Chem. Soc. 136 (2014), 7273–7285.
40. Aitha, M., et al. Biochemical, mechanistic, and spectroscopic characterization of metallo-β-lactamase VIM-2. Biochemistry 53 (2014), 7321–7331.
41. Griffin, D.H., et al. Structural and kinetic studies on metallo-β-lactamase IMP-1. Biochemistry 50 (2011), 9125–9134.
42. Aitha, M., et al. Probing substrate binding to the metal binding sites in metallo-β-lactamase L1 during catalysis. MedChemComm 7 (2016), 194–201.
43. Periyannan, G.R., et al. Sequential binding of cobalt(II) to metallo-β-lactamase CcrA. Biochemistry 45 (2006), 1313–1320.
44. Sharma, N., et al. Conformational changes in the metallo-β-lactamase ImiS during the catalytic reaction: an EPR spectrokinetic study of Co(II)-spin label interactions. J. Am. Chem. Soc. 130 (2008), 8215–8222.
45. Llarrull, L.I., et al. Evidence for a dinuclear active site in the metallo-β-lactamase BcII with substoichiometric Co(II). A new model for metal uptake. J. Biol. Chem. 282 (2007), 30586–30595.
46. Lisa, M.N., et al. A general reaction mechanism for carbapenem hydrolysis by mononuclear and binuclear metallo-β-lactamases. Nat. Commun., 8, 2017, 538.
47. Hu, Z., et al. Role of the Zn1 and Zn2 sites in metallo-β-lactamase L1. J. Am. Chem. Soc. 130 (2008), 14207–14216.
48. Hawk, M.J., et al. Differential binding of Co(II) and Zn(II) to metallo-β-lactamase Bla2 from Bacillus anthracis. J. Am. Chem. Soc. 131 (2009), 10753–10762.
49. Hu, Z., et al. Folding strategy to prepare Co(II)-substituted metallo-β-lactamase L1. Anal. Biochem. 378 (2008), 177–183.
50. Bertini, I., et al. Perspectives in paramagnetic NMR of metalloproteins. Dalton Trans., 2008, 3782–3790.
51. Bertini, I., et al. Nuclear magnetic resonance of paramagnetic metalloproteins. Chem. Rev. 93 (1993), 2833–2932.
52. Craig, W.R., et al. Substituent effects on the coordination chemistry of metal-binding pharmacophores. Inorg. Chem. 56 (2017), 11721–11728.
53. Baum, R.R., et al. Paramagnetic resonance of high-spin Co(II) in biologically-relevant environments: models to metalloproteins. Hanson, G., Berliner, L., (eds.) Future Directions in Metalloprotein and Metalloenzyme Research, 2017, Springer, 33–54.
54. Aitha, M., et al. Conformational dynamics of metallo-β-lactamase CcrA during catalysis investigated by using DEER spectroscopy. J. Biol. Inorg. Chem. 20 (2015), 585–594.
55. 19F NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 53 (2014), 3129–3133.
56. Brem, J., et al. Studying the active-site loop movement of the São Paolo metallo-β-lactamase-1. Chem. Sci. 6 (2015), 956–963.
57. 19F-NMR reveals the role of mobile loops in product and inhibitor binding by the São Paulo metallo-β-lactamase. Angew. Chem. Int. Ed. Engl. 56 (2017), 3862–3866.
58. Abboud, M.I., et al. Cyclobutanone mimics of intermediates in metallo-β-lactamase catalysis. Chem. Eur. J. 24 (2018), 1–5.
59. Aitha, M., et al. Investigating the position of the hairpin loop in New Delhi metallo-β-lactamase, NDM-1, during catalysis and inhibitor binding. J. Inorg. Biochem. 156 (2016), 35–39.
60. Jeschke, G., DEER distance measurements on proteins. Annu. Rev. Phys. Chem. 63 (2012), 419–446.
61. Crowder, M.W., et al. Metallo-β-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39 (2006), 721–728.
62. Mojica, M.F., et al. B1-Metallo-β-lactamases: where do we stand?. Curr. Drug Targets 17 (2016), 1029–1050.
63. Sevaille, L., et al. 1,2,4-Triazole-3-thione compounds as inhibitors of dizinc metallo-β-lactamases. ChemMedChem 12 (2017), 972–985.
64. Skagseth, S., et al. Metallo-β-lactamase inhibitors by bioisosteric replacement: preparation, activity and binding. Eur. J. Med. Chem. 135 (2017), 159–173.
65. Karsisiotis, A.I., et al. Solution structures of the Bacillus cereus metallo-β-lactamase BcII and its complex with the broad spectrum inhibitor R-thiomandelic acid. Biochem. J. 456 (2013), 397–407.
66. Cain, R., et al. In silico fragment based design identifies subfamily B1 metallo-β-lactamase inhibitors. J. Med. Chem. 61 (2018), 1255–1260.
67. Zhang, E., et al. NOTA analogue: a first dithiocarbamate inhibitor of metallo-β-lactamases. Bioorg. Med. Chem. Lett. 28 (2018), 214–221.
68. Huang, P.J., et al. Inhibiting the VIM-2 metallo-β-lactamase by graphene oxide and carbon nanotubes. ACS Appl. Mater. Interfaces 7 (2015), 9898–9903.
69. Ouyang, X., et al. A DNA nanoribbon as a potent inhibitor of metallo-β-lactamases. Chem. Commun. (Camb.) 53 (2017), 8878–8881.
70. Kim, S.K., et al. Inhibition of Bacillus anthracis metallo-β-lactamase by compounds with hydroxamic acid functionality. J. Enzyme Inhib. Med. Chem. 31 (2016), 132–137.
71. McGeary, R.P., et al. Structure–activity relationship study and optimisation of 2-aminopyrrole-1-benzyl-4,5-diphenyl-1H-pyrrole-3-carbonitrile as a broad spectrum metallo-β-lactamase inhibitor. Eur. J. Med. Chem. 137 (2017), 351–364.
72. Holloway, A.J., et al. Cystatin 9 and C: a novel immunotherapy that protects against multi-drug resistant New Delhi metallo-β-lactamase-1 producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 62, 2018 e01900-17.